LGI1-antibody associated epilepsy successfully treated in the outpatient setting.

"Declaration of Competing Interest RUSM, EC, RS, CC, AM, JPC, BS, MCM, and MH nothing to disclose. SRI is a coapplicant and receives royalties on patent application WO/2010/046716 (U.K. patent no., PCT/GB2009/051441) entitled’Neurological Autoimmune Disorders'. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies. He has received honoraria from UCB, MedImmun, ADC therapeutics and Medlink Neurology."

"Funding SRI is supported by the 10.13039/100010269Wellcome Trust (104079/Z/14/Z), the 10.13039/501100000769UCB-Oxford University Alliance, BMA Research Grants—Vera Down grant (2013) and Margaret Temple (2017) and 10.13039/501100000295Epilepsy Research UK (P1201). The research was funded/supported by the 10.13039/501100000272National Institute for Health Research (NIHR) Oxford Biomedical Research Centre [(BRC); the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health]."